Tokio Marine Asset Management Co. Ltd. Sells 164 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Tokio Marine Asset Management Co. Ltd. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,864 shares of the company’s stock after selling 164 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $3,810,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd boosted its holdings in shares of IDEXX Laboratories by 54.9% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 1,416 shares of the company’s stock worth $786,000 after purchasing an additional 502 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $263,000. Linden Thomas Advisory Services LLC boosted its holdings in shares of IDEXX Laboratories by 5.8% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 5,945 shares of the company’s stock worth $3,300,000 after purchasing an additional 328 shares in the last quarter. Marks Group Wealth Management Inc boosted its holdings in shares of IDEXX Laboratories by 1.8% in the 4th quarter. Marks Group Wealth Management Inc now owns 8,912 shares of the company’s stock worth $4,947,000 after purchasing an additional 157 shares in the last quarter. Finally, PDS Planning Inc boosted its holdings in shares of IDEXX Laboratories by 4.7% in the 4th quarter. PDS Planning Inc now owns 581 shares of the company’s stock worth $322,000 after purchasing an additional 26 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,524 shares of company stock valued at $24,871,960. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Trading Up 0.1 %

IDXX traded up $0.46 during midday trading on Wednesday, reaching $494.26. 493,029 shares of the company’s stock traded hands, compared to its average volume of 431,297. The firm has a fifty day moving average of $533.74 and a two-hundred day moving average of $510.50. The stock has a market capitalization of $41.05 billion, a price-to-earnings ratio of 49.08, a P/E/G ratio of 3.69 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.05 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on IDXX. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a report on Tuesday, January 30th. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group increased their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, Barclays increased their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.